Рет қаралды 241
Psychedelic-assisted group psychotherapy (PAGP) is an exciting field that has received little attention in recent research. Despite only three studies being conducted on this topic in the 21st century, PAGP has been a longstanding practice in Switzerland under "limited medical use" regulations. Utilizing a three-day-format, psychiatrists and psychotherapists work with groups of up to twelve patients at a time, providing a unique opportunity for patients to work together in a group setting.
This talk will delve into the fundamental therapeutic factors specific to PAGP, with a theoretical foundation based on the eleven group therapeutic factors of the renowned group therapist Irvin Yalom. This approach allows us to identify the key differences between individual psychedelic-assisted psychotherapy and PAGP, as well as highlight some of the challenges that clinicians have faced in implementing this therapy method.
However, like any therapeutic approach, PAGP is not without its challenges. Clinicians must carefully manage group dynamics to ensure that all patients feel safe and comfortable sharing their experiences. Additionally, individual reactions to psychedelic substances can vary widely, which means that clinicians must be prepared to adjust their approach on a case-by-case basis.
Overall, PAGP is a promising approach that merits further research and exploration. By raising awareness around this unique therapeutic model, this could encourage more researchers and clinicians to consider incorporating PAGP into their research and / or practice, thereby furthering our understanding of its potential benefits.
At ALPS, we aim to bring together several outstanding researchers and clinicians working with psychedelic substances. Its purpose is to promote the latest scientific and clinical knowledge on the subject and discuss about key issues of the domain.